Back to Search
Start Over
Human olfactory neural progenitor cells reveal differences in IL-6, IL-8, thrombospondin-1, and MCP-1 in major depression disorder and borderline personality disorder.
- Source :
-
Frontiers in psychiatry [Front Psychiatry] 2024 Apr 09; Vol. 15, pp. 1283406. Date of Electronic Publication: 2024 Apr 09 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Background: Discovering biological markers is essential for understanding and treating mental disorders. Despite the limitations of current non-invasive methods, neural progenitor cells from the olfactory epithelium (hNPCs-OE) have been emphasized as potential biomarker sources. This study measured soluble factors in these cells in Major Depressive Disorder (MDD), Borderline Personality Disorder (BPD), and healthy controls (HC).<br />Methods: We assessed thirty-five participants divided into MDD (n=14), BPD (n=14), and HC (n=7). MDD was assessed using the Hamilton Depression Rating Scale. BPD was evaluated using the DSM-5 criteria and the Structured Clinical Interview for Personality Disorders. We isolated hNPCs-OE, collected intracellular proteins and conditioned medium, and quantified markers and soluble factors, including Interleukin-6, interleukin-8, and others. Analysis was conducted using one-way ANOVA or Kruskal-Wallis test and linear regression.<br />Results: We found that hNPCs-OE of MDD and BPD decreased Sox2 and laminin receptor-67 kDa levels. MASH-1 decreased in BPD, while tubulin beta-III decreased in MDD compared to controls and BPD. Also, we found significant differences in IL-6, IL-8, MCP-1, and thrombospondin-1 levels between controls and MDD, or BPD, but not between MDD and BPD.<br />Conclusions: Altered protein markers are evident in the nhNPCs-OE in MDD and BPD patients. These cells also secrete higher concentrations of inflammatory cytokines than HC cells. The results suggest the potential utility of hNPCs-OE as an in vitro model for researching biological protein markers in psychiatric disorders. However, more extensive validation studies are needed to confirm their effectiveness and specificity in neuropsychiatric disorders.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Davalos-Guzman, Vegas-Rodriguez, Ramirez-Rodriguez, Flores-Ramos, Romero-Luevano, Gonzalez-Olvera and Saracco-Alvarez.)
Details
- Language :
- English
- ISSN :
- 1664-0640
- Volume :
- 15
- Database :
- MEDLINE
- Journal :
- Frontiers in psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- 38654728
- Full Text :
- https://doi.org/10.3389/fpsyt.2024.1283406